Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults
一项 I/IIa 期研究旨在评估 ChAdOx1-MVA 载体疫苗（表达一种新型肝期疟疾双抗原 LS2）在未感染过疟疾的成年人中通过孢子攻击的安全性、免疫原性和有效性。
期刊:Wellcome Open Research
影响因子:
doi:10.12688/wellcomeopenres.22900.2
Silman, Daniel; Flaxman, Amy; Datoo, Mehreen; Edwards, Nick J; Ramos-Lopez, Fernando; Mitton, Celia; Mair, Catherine; Bellamy, Duncan; Bowyer, Georgina; Morter, Richard; Halbroth, Benedict; Venkatraman, Navin; Folegatti, Pedro M; Marshall, Julia; Poulton, Ian; Bajer, Amelia; Salman, Ahmed M; Berrie, Eleanor; Baum, Jake; Blagborough, Andrew M; Crocker, Wendy; Roberts, Rachel; Lawrie, Alison M; Spencer, Alexandra J; Gilbert, Sarah C; Ewer, Katie J; Hill, Adrian V S
